Prix Lite Strategy Inc (LITS)

Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.